IRQ Articles

SIR Today March 25 articles 

03-25-2021 12:44

SIR Today 2021 banner

Thursday, March 25: Venous/Dialysis

The dialysis patient population continues to grow worldwide and these patients face shortened life expectancy, along with poor quality of life. Millions succumb to renal failure and its complications each year. Similarly, venous diseases, including venous thromboembolism and pulmonary embolism, acute as well as chronic, affect a large segment of population leading to significant morbidity and mortality globally. IR plays a vital role in the management of these diseases. We are confident that audience will find this program on dialysis and venous diseases, including thromboembolism and portal hypertension, by our world class faculty very rewarding and educational.
—SIR 2021 Scientific Chair Baljendra Kapoor, MD, FSIR

Daily science preview | 10–11 a.m.

Posted March 25, 2021

Learn all the details of the three concurrent scientific sessions scheduled for 10–11 a.m.
  • Men's and Women's Health II
  • Venous/Pulmonary AVM/Dialysis
  • Interventional Oncology III

Interview with 2020 Dotter Lecturer Karim Valji, MD, FSIR

Posted March 25, 2021

At 11 a.m. today, Karim Valji, MD, FSIR, will present the 2020 Dotter Lecture. Read an interview with Dr. Valji on what drives him and what first drew him to IR. Read more. 

Combat burnout with “IR Wellness” plenary | noon

Posted March 25, 2021
Join a panel of IR leaders as they discuss “IR Wellness” during today’s plenary, moderated by Grace Knuttinen, MD, PhD. According to Dr. Knuttinen, "Physician burnout is associated with increased medical errors, decreased patient satisfaction and decreased career longevity. Yet the conversation around burnout in interventional radiology has been lacking." Read more.

Session preview: Controversies in Portal Hypertension | 1–2 p.m.

Posted March 25, 2021

Join “Controversies in Portal Hypertension” this afternoon for six lectures discussing opposing techniques and approaches in portal hypertension. Read more.

Recap: Update on PAE

Posted March 25, 2021

PAE hasn’t gained universal support yet—but the tide may be changing, according to Wednesday’s “Update on PAE” session. In five presentations, experts discussed the status and practice of PAE as a treatment for BPH. Read more.

Session preview: PE Cases to Make You Think | 3 p.m.

Posted March 25, 2021

“We are going to be discussing some cases that challenged us as interventionalists and physicians, and the ensuing discussions will be lively,” says session coordinator Akhilesh K. Sista, MD, FSIR. “We won’t shy away from controversy, and we are absolutely going to ask one another about different approaches to tough PE cases.” Read more.

Who, where, what: The 2020 Gold Medalists

Posted March 25, 2021
Last year, SIR Today saluted each of the 2020 Gold Medalists with a personal look at their outstanding careers, asking them for a person, place and thing that has particularly inspired or influenced them. Read more.

Session recap: Lymphatics Basics

Posted March 25, 2021
During the “Lymphatic Basics” session on Wednesday, March 24, attendees were given an overview of common lymphatic imaging techniques, disease presentations, therapies and complications. Read more.

Leadership remarks: Matthew S. Johnson, MD, FSIR 

Posted March 25, 2021

On Wednesday, March 24, incoming SIR President Matthew S. Johnson, MD, FSIR, spoke to SIR 2021 attendees about the coming strategic priorities for the society and the specialty. Read the full transcript of his remarks.

3 Qs to qualify: C-TRACT Trial still enrolling 

Posted March 25, 2021

The Chronic Venous Thrombosis: Relief with Adjunctive Catheter-delivered Therapy (C-TRACT) Trial, a randomized, multicenter trial sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH), is still enrolling patients. According to Principal Investigator Suresh Vedantham, MD, FSIR, although IRs have long delivered endovascular therapy to PTS patients, there is a need for high-quality studies and further investigation of long-term efficacy. Read more.

Connect with SIR

AD: Medtronic